Side Effects Of Byetta, Januvia Linked To Risk Of Pancreatitis: Study - Aboutlawsuits.com

Januvia for Type 1 Diabetes - Diabetes





Chronic pancreatitis has been linked to a potential increased risk of pancreatic cancer and other health problems. As a result of the findings of this latest study, researchers indicate that additional research is needed to evaluate the potential link between Januvia, Byetta and pancreatic cancer In 2011, a Januvia pancreatic cancer study indicated Januvia complications that the drug may increase the risk of pancreatitis and pancreatic cancer. However, Merck has maintained that a thorough review of clinical trial data has found no evidence of a causal relationship between side effects of Januvia and pancreatic cancer or pancreatitis. Related Articles I authorize the above comments be posted on this page* Yes No Have Your Comments Reviewed by a Lawyer Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published and will be confidential. read more http://www.aboutlawsuits.com/januvia-byetta-pancreatitis-study-2-41769/









C-peptide positive subjects treated with sitagliptin hada nonsignificant trend in decreasing hyperglycemia, which needs further evaluation." Another small published study (20 patients) evaluated the addition of either sitagliptin or exenatide (brand name Byetta, from a different class of drugs for treating T2D) to insulin in patients with recently-diagnosed T1D, and indicated that "In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin... Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events." A few more studies of Januvia in people with T1D are underway, for example, a study in teenagers with T1D . Since none of the studies in ClinicalTrials.gov indicate any sponsorship by the manufacturer, Merck Sharp & Dohme, I suspect there's not much information that the manufacturer has in-house (either from studies they've done, or from reports of adverse events) to try to get the indication extended so the drug can be offically promoted for use in T1D as well as T2D. It would appear from the results mentioned in these few published studies that there might be some effect of sitagliptin in lowering BG in patients with T1D, but it's apparently not a spectacular effect. And there's nothing mentioned in the abstractsthat I reviewed that implies that there are any unexpected side effects. read more http://www.healthcentral.com/diabetes/c/110/169439/januvia-type-1-diabetes